The Hidden Architecture of Cannabis: A 4-Part Series on Phenotype-Dependent Microbial Resistance

Part 1: The Observation — Why Do Some Cultivars Consistently Pass TYM Testing While Others Consistently Fail?

By Christopher Leavitt, Founder, Voyager Genetics

At GreenTech Amsterdam this year, I watched Maxwell Cranford present on one of the topics I've been quietly thinking about for a long time: breeding cannabis for microbial resistance. His presentation cited a landmark 2023 peer-reviewed study out of Simon Fraser University that stopped me cold. For the first time, there was hard scientific evidence for something many commercial cultivators had been observing anecdotally for years: that certain cannabis cultivars consistently test low for Total Yeast and Mold, while others consistently test high, and that this pattern appears to be driven by the plant itself rather than the environment around it.

That study, and that presentation, inspired this series.

What is Total Yeast and Mold, and why does it matter?

Total Yeast and Mold (TYM) is a microbiological measurement, expressed in colony-forming units per gram (cfu/g) of the combined yeast and fungal load present on a cannabis sample. It is now a mandatory release criterion for GMP and GACP-certified cannabis flower in most regulated medical markets worldwide.

The limits vary considerably by jurisdiction. In North America, acceptable levels generally range from 1,000 to 100,000 cfu/g depending on the state or province. European medical markets tend to be significantly more stringent. Inhaled medical cannabis in the UK, for instance, is expected to comply with European Pharmacopoeia specifications, with limits as low as 100 cfu/g for certain organisms. Germany, Poland, and other established EU medical markets operate under similarly demanding frameworks.

These aren't abstract regulatory thresholds. Failing a TYM test means a batch cannot be released. It means remediation, most commonly gamma irradiation or electron beam treatment, which adds logistics, cost, processing time, and regulatory complexity. And critically, many pharmaceutical buyers and patients continue to view non-irradiated flower as a premium product, meaning remediated flower often commands a lower price even when it meets the technical standard.

Consider what this means economically. Two otherwise identical harvests with the same yield, same potency, same aroma profile, can have fundamentally different business outcomes simply because one passes TYM naturally and the other requires remediation before it can reach patients. The difference between these two outcomes isn't small. When you factor in remediation costs, logistics, time-to-market delays, and potential price differentiation at the point of sale, TYM compliance is quietly becoming one of the most significant variables in the economic performance of a licensed medical cultivation operation.

The pattern that started this conversation

Commercial cultivators operating at scale, particularly those running multiple cultivars simultaneously in the same facility, have been noticing something for years. Certain cultivars reliably pass TYM testing. Others reliably fail. This pattern holds across harvest cycles, across seasons, and sometimes even across different facilities running the same genetics under different conditions.

The strange part is that the cultivars sharing the same room are growing under identical environmental conditions: the same temperature, the same humidity, the same sanitation protocols, the same irrigation regime, the same staff, the same SOPs. If environment were the primary driver, you'd expect broadly similar TYM outcomes across the room. Instead, what cultivators observe is a striking cultivar-specific pattern that environmental variables alone don't explain.

This observation has been circulating informally for years. What we lacked until recently was scientific evidence to support it.

The Punja et al. study: the first peer-reviewed confirmation

In 2023, Zamir Punja and colleagues at Simon Fraser University published what is, to my knowledge, the first rigorous peer-reviewed investigation of the factors influencing TYM levels in cannabis inflorescences. The study analyzed over 2,000 fresh and dried samples across a three-year period from 2019 to 2022, grown in a licensed commercial greenhouse facility in Canada. It is one of the most comprehensive datasets on TYM in cannabis that exists.

The study examined six cultivars: Watermelon Kush, Pink Kush, Powdered Donuts, Jack Herer, Black Cherry, and Death Bubba grown simultaneously under the same greenhouse conditions. The results were striking.

Jack Herer and Death Bubba consistently showed the lowest TYM levels across all four months of sampling (June through September). Watermelon Kush and Powdered Donuts consistently showed the highest. These differences were statistically significant across all sampling periods, and the pattern held regardless of seasonal variation, which itself was shown to be a significant independent factor. Samples taken during May through October consistently showed higher TYM than those taken during November through April, likely due to greater ambient fungal spore pressure in warmer months.

The study identified several variables that significantly increased TYM levels: the genotype grown, the presence of leaf litter in the growing environment, harvesting activity by workers, genotypes with a higher abundance of stigmatic tissues and inflorescence leaves, higher temperature and relative humidity within the inflorescence microclimate, and time of year. Variables that significantly decreased TYM included: genotypes with lower numbers of inflorescence leaves, air circulation from fans during inflorescence maturation, harvesting during the November-April period, the hang-dry post-harvest method versus wet trim, and drying to a moisture content of 12-14%.

Two findings stand out as particularly important for our purposes.

First, genotype was confirmed as a significant independent variable. The researchers were explicit: TYM in cannabis inflorescences results from a dynamic interaction between genotype, environment, and post-harvest handling. The plant itselt- its genetics, its morphology, and its physical architecture is a primary driver of TYM outcomes, not just the environment around it.

Second, the study found that genotypes with lower numbers of inflorescence leaves showed significantly lower TYM counts. And when temperature and humidity were measured within the inflorescences themselves using a psychrometer probe, the researchers found that internal inflorescence humidity and temperature were consistently and significantly higher than the ambient environment and that this internal microclimate varied between cultivars. Certain plants were effectively creating their own warm, humid internal environment that was more favorable to microbial colonization, independent of what was happening in the room around them.

This is a critical finding. It means that a cultivar's physical architecture (the density of its inflorescence leaves, its bud structure, the microclimate it creates within its own flower) can determine TYM outcomes in ways that growers cannot fully control through environmental management alone. No matter how well you dial in your room, a structurally susceptible cultivar may still create favorable internal conditions for microbial accumulation.

An important distinction: TYM is not just pathogen resistance

Before we dive into the hypotheses for what's driving this, it's worth clarifying something that the industry often conflates.

TYM resistance is not the same as classical disease resistance. Botrytis resistance and powdery mildew resistance are phenotypes that breeders have selected for informally for decades- they're about the plant's ability to resist colonization by known pathogens. TYM resistance is broader.

The Punja study identified 21 species of fungi and yeasts from the cannabis samples it analyzed. The predominant genera were Penicillium, Aspergillus, Cladosporium, and Fusarium, along with four yeast genera. Many of these are environmental contaminants rather than primary plant pathogens. They are organisms that don't infect the plant in the traditional sense, but simply land on and accumulate on its surface. A TYM test counts all of them. It cannot distinguish between a pathogenic mold and a harmless environmental yeast. It simply counts everything present as colony-forming units.

This means a cultivar can show visible powdery mildew infection and test lower for TYM than a visually clean cultivar in the same room because the clean-looking plant may be accumulating more environmental spores on its surface even while resisting active colonization. Powdery mildew resistance and TYM resistance overlap, but they are not equivalent.

There's also an important note in the Punja study about interspecific correlations. The researchers observed that genotypes with higher TYM levels also tended to show higher susceptibility to Botrytis bud rot and powdery mildew. The range of terpene profiles, THC content, and CBD content among the six genotypes did not correlate with TYM outcomes. This supports the view that it's the plant's physical architecture, not its chemistry, that is the primary driver of TYM resistance. But it also suggests that whatever structural characteristics protect against TYM may also provide some degree of protection against classical pathogens, even if the mechanisms are not identical.

Why this is becoming a breeding target

As a breeder, my job has always been to select cultivars that perform well for patients and commercial operators: potency, terpene profile, yield, flowering time, disease resistance, and ease of cultivation. TYM resistance is now joining that list, and I think it's going to move up the priority rankings quickly.

The economics are straightforward. In a market where irradiation adds cost and reduces perceived product quality, a cultivar that reliably passes TYM testing without intervention is worth more than one that doesn't, even if everything else about them is identical. As European medical markets continue to tighten their microbial specifications, and as the industry's understanding of which organisms actually pose a health risk becomes more sophisticated, TYM performance will increasingly separate winning genetics from losing ones.

The challenge is that we don't yet fully understand what makes a cultivar TYM-resistant. The Punja study gives us important clues, particularly around inflorescence leaf density, bud architecture, and the microclimate dynamics within the flower. But the mechanistic question, why do some cultivars accumulate fewer surface microbes than others under the same conditions? That remains largely open.

That's the question this series is built to explore.

In Part 2, we'll examine the hypotheses that might explain phenotype-dependent TYM resistance, introduce the distinction between what we're calling "anti-aircraft defense" and "ground defense," and begin building a framework for thinking about this problem from a breeding perspective.

Christopher Leavitt is the founder of Voyager Genetics, a cannabis genetics IP licensing and consulting company based in Lisbon, Portugal. Voyager supplies GACP-compliant, phenohunted clone genetics to licensed medical cannabis producers across Europe. Contact: contact@voyagergenetics.com

Full citation: Punja, Z.K., Ni, L., Lung, S., and Buirs, L. (2023). Total yeast and mold levels in high THC-containing cannabis (Cannabis sativa L.) inflorescences are influenced by genotype, environment, and pre- and post-harvest handling practices. Frontiers in Microbiology, 14:1192035. https://doi.org/10.3389/fmicb.2023.1192035